Diabetes mtllitus and covid-19: deadly alliance of two pandemics. Strategise for improving forecast (Part 2)
https://doi.org/10.51922/2074-5044.2022.1.74
Abstract
Diabetes mellitus is one of the most common comorbidities in patients with COVID-19. The complex bidirectional cross impact of both diseases leads to the severity and an increased risk of mortality in patients with coronavirus infection. The clinical experience of specialists in many countries has led to the development of optimal algorithms for the management of diabetic patients in pandemic conditions.
About the Authors
Y. M. Hromava
Военно-медицинский институт в УО «Белорусский государственный медицинский университет»
Belarus
Belarus
A. A. Bova
Военно-медицинский институт в УО «Белорусский государственный медицинский университет»
Belarus
Belarus
References
1. Babenko A. Yu., Laevskaya M. Yu. Saharnyj diabet i COVID 19. Kak oni svyazany? Sovremennye strategii bor‘by. Arterial‘naya gipertenziya. 2020; 26(3):304–311. doi: 10.18705/1607-419X-2020-26-3-304-311
2. Bova A. A. i soavt. Kardiovaskulyarnye riski u pacientov s saharnym diabetom: sovremennye vozmozhnosti uluchsheniya prognoza: Rukovodstvo dlya vrachej / A. A. Bova [i dr.]. – Minsk: NikitaGrafiksPlyus. – 2020. – 188 s.
3. Gavrilenko L., Kozhanova I., Romanova I. Lekarstvennaya terapiya COVID-19 s tochki zreniya dokazatel‘noj mediciny / Medicinskij vestnik // № 46 (12 noyabrya 2020 g.). – S. 4–5.
4. Grinevich V. B. i dr. Osobennosti vedeniya komorbidnyh pacientov v period pandemii novoj koronavirusnoj infekcii (COVID-19). Nacional‘nyj Konsensus 2020 / Kardiovaskulyarnaya terapiya i profilaktika. 2020;19(4). – S. 135–172.
5. Klimontov V. V., Myakina N. E. Variabel‘nost‘ glikemii pri saharnom diabete: instrument dlya ocenki kachestva glikemicheskogo kontrolya i riska oslozhnenij / Saharnyj diabet. 2014: (2). – S. 76–82.
6. Profilaktika, diagnostika i lechenie novoj koronavirusnoj infekcii (COVID-19) / Vremennye metodicheskie rekomendacii MZ RF Versiya 9 (26.10.2020). – 166 s.
7. Kang Yu. et al. Cardiovascular manifestations and treatment considerations in COVID-19 / Heart 2020. PMID: 32354800
8. Mandeep R. Mehra et al. Cardiovascular Disease, Drug Therapy in Covid-19 / The New England Journal of Medicine 2020; 382:e102 doi: 10.1056/NEJMoa2007621
9. Mortensen et al. Pneumonia. Hypoglycemia. Mortality / Am J Med Sci 2010: 339(3). – P. 239–243.1
10. Stefan R Bornstein, Francesco Rubino, Kamlesh Khunt et al. Practical recommendations for the management of diabetes in patients with COVID-19 / Lancet Diabetes Endocrinol 2020: 8. – P. 546–50.
11. W. Yang et al. DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials / Diabetes Metab Res Rev 2016: 32. – P. 391–404.
Review
For citations:
Hromava Y.M., Bova A.A. Diabetes mtllitus and covid-19: deadly alliance of two pandemics. Strategise for improving forecast (Part 2). Military Medicine. 2022;(1):74-79. (In Russ.) https://doi.org/10.51922/2074-5044.2022.1.74
Views:
19
JATS XML
Email this article 